Roka Bioscience to Present at the Piper Jaffray Healthcare Conference WARREN, N.J., Nov. 25, 2014 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced that Paul G. Thomas will present at the Piper Jaffray 26th Annual Healthcare Conference on December 2, 2014 at 4:30pm ET. The conference will be held at The New York Palace in New York, NY. During this presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. To listen to the audio webcast of the presentation during the event, please visit: rokabio.investorroom/. A replay of the webcast will be available for 10 days after the presentation. About Roka Bioscience Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our sample-in, result-out Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit rokabio. Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the Exchange Act). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and managements current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we believe, expect, anticipate, plan and similar expressions) that are not statements of historical fact should be considered forward-looking statements and should be read in conjunction with the Condensed Financial Statements included in this press release and the discussion below. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the companys filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release. Investor Contact:Roka Bioscience, Inc.ir@rokabio855-ROKABIO (855-765-2246) SOURCE Roka Bioscience, Inc. RELATED LINKSrokabio
Posted on: Wed, 26 Nov 2014 04:34:26 +0000
Trending Topics
Recently Viewed Topics
© 2015